Trial of Anifrolumab in Active Systemic Lupus Erythematosus | Zendy

Eric F. Morand | Zendy; Richard Furie | Zendy; Yoshiya Tanaka | Zendy; Ian N Bruce | Zendy; Anca Askanase | Zendy; Christophe Richez | Zendy; SangCheol Bae | Zendy; Philip Z. Brohawn | Zendy; Lilia Pineda | Zendy; Anna Berglind | Zendy; Raj Tummala | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Author(s) -

Eric F. Morand,

Richard Furie,

Yoshiya Tanaka,

Ian N Bruce,

Anca Askanase,

Christophe Richez,

SangCheol Bae,

Philip Z. Brohawn,

Lilia Pineda,

Anna Berglind,

Raj Tummala

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1912196

Subject(s) - medicine , monoclonal antibody , lupus erythematosus , monoclonal , clinical endpoint , immunology , antibody , clinical trial , dermatology

Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect on the primary end point in a previous phase 3 trial. The current phase 3 trial used a secondary end point from that trial as the primary end point.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research